Xanthine oxidase inhibitor scaffold diversity and structure-based drug design by transion metal
Keywords:
metal complexes, xanthine oxidase, inhibitorsAbstract
Schiff base complexes of transition metals are used in a variety of fields, including medicine, agriculture, and industry. For example, [Co(acac2- en)] has been reported to be involved in oxygen metabolism in dimethylformamide, pyridine, and modified pyridines. They're called transition metal complexes, and they're used in the refining of petroleum. Condensed Schiff base derived by the condensation of arylamides with o-hydroxyl or o-methoxy aniline complexes of Co(II), Ni(II), Cu(II), and Zr complexes is a fabrication of the imagination.
References
Baldisserotto A, Vertuani S, Bino A, De Lucia D, Lampronti I, Milani R, et al. Design, synthesis and biological activity of a novel Rutin analogue with improved lipid soluble properties. Bioorganic and Medicinal Chemistry. 2015;23(1):264-271.
Battelli MG, Bolognesi A, Polito L. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2014;1842(9):1502-1517.
Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, et al. Febuxostat (TMX‐67), a novel, non‐purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides, Nucleotides and Nucleic Acids. 2004;23(8-9):1111-1116.
Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. The Journal of Physiology. 2004;555(3):589-606.
Brass CA, Narciso J, Gollan JL. Enhanced activity of the free radical producing enzyme xanthine oxidase in hypoxic rat liver. Regulation and pathophysiologic significance. The Journal of Clinical İnvestigation. 1991;87(2):424-431.
Cao H, Pauff JM, Hille R. X-ray crystal structure of a xanthine oxidase complex with the flavonoid inhibitor quercetin. Journal of Natural Products. 2014;77(7):1693-1699.
Chambers DE, Parks DA, Patterson G, Roy R, McCord JM, Yoshida S, et al. Xanthine oxidase as a source of free radical damage in myocardial ischemia. Journal of Molecular and Cellular Cardiology. 1985;17(2):145-152.
Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?. British Journal of Clinical Pharmacology. 2006;62(6):633-644.
Desco MC, Asensi M, Márquez R, Martínez-Valls J, Vento M, Pallardó FV, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes. 2002;51(4):1118-1124.
Dhiman P, Malik N, Verma PK, Khatkar A. Synthesis and biological evaluation of thiazolo and imidazo N-(4-nitrophenyl)-7-methyl-5-aryl-pyrimidine-6 carboxamide derivatives. Research on Chemical Intermediates. 2015;41(11):8699-8711.
Elion GB. The quest for a cure. Annual Review of Pharmacology and Toxicology. 1993;33(1):1-25.
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry. 2004;47(7):1739-1749.
Griguer CE, Oliva CR, Kelley EE, Giles GI, Lancaster JR, Gillespie GY. Xanthine oxidase–dependent regulation of hypoxia-inducible factor in cancer cells. Cancer Research. 2006;66(4):2257-2263.
Gullón B, Lú-Chau TA, Moreira MT, Lema JM, Eibes G. Rutin: A review on extraction, identification and purification methods, biological activities and approaches to enhance its bioavailability. Trends in Food Science and Technology. 2017;67:220-235.
Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. Journal of Cheminformatics. 2012;4(1):1-17.
Inkster ME, Cotter MA, Cameron NE. Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats. European Journal of Pharmacology. 2007;561(1-3):63-71.
Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. In Seminars in Nephrology. 2005;25(1):39-42.
Kaynar H, Meral M, Turhan H, Keles M, Celik G, Akcay F. Glutathione peroxidase, glutathione-S-transferase, catalase, xanthine oxidase, Cu–Zn superoxide dismutase activities, total glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients with small cell and non-small cell lung cancer. Cancer Letters. 2005;227(2):133-139.
Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney İnternational. 2005;67(5):1739-1742.
Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clinical Pharmacokinetics. 2006;45(8):821-841.
KLINENBERG JR, GOLDFINGER SE, SEEGMILLER JE. The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Annals of İnternal Medicine. 1965;62(4):639-647.
Krakoff IH, Meyer RL. Prevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitor. JAMA. 1965;193(1):1-6.
Kuppusamy P, Zweier JL. Characterization of free radical generation by xanthine oxidase: Evidence for hydroxyl radical generation. Journal of Biological Chemistry. 1989;264(17):9880-9884.
Li P, Tian Y, Zhai H, Deng F, Xie M, Zhang X. Study on the activity of non-purine xanthine oxidase inhibitor by 3D-QSAR modeling and molecular docking. Journal of Molecular Structure. 2013;1051:56-65.
Malik N, Dhiman P, Khatkar A. In-silico design and ADMET studies of natural compounds as inhibitors of xanthine oxidase (XO) enzyme. Current Drug Metabolism. 2017;18(6):577-593.
Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. American Journal of Therapeutics. 2005;12(1):22-34.
Miesel R, Zuber M. Elevated levels of xanthine oxidase in serum of patients with inflammatory and autoimmune rheumatic diseases. Inflammation. 1993;17(5):551-561.
Min HK, Lee B, Kwok SK, Ju JH, Kim WU, Park YM, et al. Allopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics and clinical outcomes. The Korean Journal of Internal Medicine. 2015;30(4):521.
Morikawa Y, Yamamoto T, Higashino K. Distribution and pathophysiologic role of molybdenum-containing enzymes. Histology and histopathology. 1997;12(2):513-524.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew R K, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry. 2009;30(16):2785-2791.
Muhammad A, Arthur DE, Babangida S, Erukainure OL, Malami I, Sani H, et al. Modulatory role of rutin on 2, 5-hexanedione-induced chromosomal and DNA damage in rats: validation of computational predictions. Drug and Chemical Toxicology. 2020;43(2):113-126.
Nepali K, Singh G, Turan A, Agarwal A, Sapra S, Kumar R, et al. A rational approach for the design and synthesis of 1-acetyl-3, 5-diaryl-4, 5-dihydro (1H) pyrazoles as a new class of potential non-purine xanthine oxidase inhibitors. Bioorganic and Medicinal Chemistry. 2011;19(6):1950-1958.
Osada Y, Tsuchimoto M, Fukushima H, Takahashi K, Kondo S, Hasegawa M, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. European Journal of Pharmacology. 1993;241(2-3):183-188.
Pacher PAL, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacological Reviews. 2006;58(1):87-114.
Patel A, Patel A, Patel A, Patel NM. Determination of polyphenols and free radical scavenging activity of Tephrosia purpurea linn leaves (Leguminosae). Pharmacognosy Research. 2010;2(3):152.
Poles MZ, Bódi N, Bagyánszki M, Fekete É, Mészáros A T, Varga G, et al. Reduction of nitrosative stress by methane: neuroprotection through xanthine oxidoreductase inhibition in a rat model of mesenteric ischemia-reperfusion. Free Radical Biology and Medicine. 2018;120:160-169.
Quach C, Galen BT. HLA-B* 5801 testing to prevent allopurinol hypersensitivity syndrome: a teachable moment. JAMA Internal Medicine. 2018;178(9):1260-1261.
Rahim F, Zaman K, Taha M, Ullah H, Ghufran M, Wadood A, et al. Synthesis, in vitro alpha-glucosidase inhibitory potential of benzimidazole bearing bis-Schiff bases and their molecular docking study. Bioorganic Chemistry. 2020;94:103394.
Roleira FM, Varela CL, Costa SC, Tavares-da-Silva EJ. Phenolic derivatives from medicinal herbs and plant extracts: anticancer effects and synthetic approaches to modulate biological activity. Studies in Natural Products Chemistry. 2018;57:115-156.
Sagor M, Taher A, Tabassum N, Potol M, Alam M. Xanthine oxidase inhibitor, allopurinol, prevented oxidative stress, fibrosis, and myocardial damage in isoproterenol induced aged rats. Oxidative Medicine and Cellular Longevity. 2015;2:1-5.
Saugstad OD. Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Pediatrics. 1996;98(1):103-107.
Shen L, Ji HF. Insights into the inhibition of xanthine oxidase by curcumin. Bioorganic and medicinal chemistry letters. 2009;19(21):5990-5993.
Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sciences. 2005;76(16):1835-1847.
Wan Y, Zou B, Zeng H, Zhang L, Chen M, Fu G. Inhibitory effect of verbascoside on xanthine oxidase activity. International Journal of Biological Macromolecules. 2016;93:609-614.
Wijermars LG, Bakker JA, de Vries DK, van Noorden CJ, Bierau J, Kostidis S, et al. The hypoxanthine-xanthine oxidase axis is not involved in the initial phase of clinical transplantation-related ischemia-reperfusion injury. American Journal of Physiology-Renal Physiology. 2017;312(3):F457-F464.
Yu KH. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Patents on İnflammation and Allergy Drug Discovery. 2007;1(1):69-75.
